Close Menu

Alnylam Presents Preclinical In Vivo on RSF Drug Candidate

Alnylam said last week that it presented in vivo efficacy data for its lead RNAi therapeutic candidate for respiratory syncytial virus at the annual meeting of the American Academy of Allergy, Asthma, and Immunology in San Antonio, Texas.

According to the company, the data demonstrated that a single low dose of an optimized siRNA, called ALN-RSV01, inhibited RSV replication both as a prophylactic and as a treatment when administered by intranasal delivery in a liquid form.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.

Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.

Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.

In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.